Notice on the 3rd Extraordinary General Meeting in 2025
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference: View Attachment
Notice on the 3rd Extraordinary General Meeting in 2025
Filed with SSE ·
6ix hasn’t read this filing yet.
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited on 6ix
Earlier from Guangzhou Baiyunshan Pharmaceutical
- Announcement on Closing Investment Projects Financed by Raised Funds and Using Residual Raised Funds to Permanently Supplement Current Capital
- Announcement on Land Expropriation Compensation for a Subsidiary
- Announcement on Convening the Q3 2025 Performance Briefing
- Announcement on Subsidiary Receiving Vietnamese Drug Registration Certificate
- Report for Q3 2025
Later from Guangzhou Baiyunshan Pharmaceutical
- Announcement on Cancellation of Subsidiary's Drug Production License
- Announcement on Subsidiary’s Acquisition of 100% Equity of Zhejiang Pharmaceutical Industry Corp., Ltd.
- Announcement on Estimated Daily Related Party Transactions in 2026
- Announcement on Guangzhou Baiyunshan Bioproducts Co., Ltd. Receiving Drug Registration Certificate
- Announcement on Progress in Subsidiary’s Participation in the Investment and Establishment of Guangzhou Guangyao Guangkai Venture Capital Investment Fund Partnership (Limited Partnership) and Related Party Transactions
Follow Guangzhou Baiyunshan Pharmaceutical into a list and get an email when it puts out news.
Follow Guangzhou Baiyunshan Pharmaceutical